Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955091 | 0.81 | FFAR1 (0.49) | FFAR1POLBLMNARAB9AMAPT | |
| SCHEMBL956589 | 0.81 | FFAR1 (0.37) | FFAR1CXCR2RXFP1POLBMAPT | |
| SCHEMBL956154 | 0.80 | FFAR1 (0.40) | FFAR1CXCR2POLB | |
| SCHEMBL956581 | 0.79 | CXCR2 (0.57) | CXCR2RXFP1POLBMAPT | |
| SCHEMBL3341624 | 0.77 | CXCR2 (0.50) | CXCR2RXFP1RAB9A | |
| SCHEMBL958613 | 0.76 | MRGPRX4 (0.50) | LMNARAB9A | |
| SCHEMBL954380 | 0.74 | RXFP1 (0.47) | CXCR2RXFP1LMNAMAPT | |
| SCHEMBL3338499 | 0.72 | CXCR2 (0.39) | CXCR2RXFP1LMNARAB9A | |
| SCHEMBL3339153 | 0.69 | MAOB (0.39) | CXCR2POLBLMNARAB9AMAPT | |
| SCHEMBL956425 | 0.69 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2257552-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009106539-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | FFAR1 731/4885CXCR2 1/4885RXFP1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.